The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease
Open accessAbstract
Contains fulltext : 89845.pdf (Publisher’s version ) (Open Access)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165
Pivonello, R., De Martino, M. C., Cappabianca, P., De Leo, M., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1533 · Cited by 328
Self-citationPasireotide (SOM230): Development, mechanism of action and potential applications
Schmid, H. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.09.006 · Cited by 290
Boscaro, M., Ludlam, W. H., Atkinson, B., Glusman, J. E., Petersenn, S., Reincke, M., Snyder, P., Tabarin, A., Biller, B. M. K., Findling, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1008 · Cited by 279
Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas
de Bruin, C., Pereira, A. M., Feelders, R. A., Romijn, J. A., Roelfsema, F., Sprij-Mooij, D. M., van Aken, M. O., van der Lelij, A., de Herder, W. W., Lamberts, S. W. J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2101 · Cited by 124
Self-citation
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationTreatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationA 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Ketoconazole in Cushing's disease: is it worth a try?
Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Caron, P., Luca, F., Donadille, B., Vantyghem, M. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3628 · Cited by 285
Feelders, R. A., Pulgar, S. J., Kempel, A., & Pereira, A. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1095 · Cited by 256
Self-citationDaniel, E., Aylwin, S., Mustafa, O., Ball, S., Munir, A., Boelaert, K., Chortis, V., Cuthbertson, D. J., Daousi, C., Rajeev, S. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2616 · Cited by 231
“Nine out of 17 patients normalized with pasireotide/cabergoline and ketoconazole induced biochemical control in 6/8 remaining patients (75%) within 20 days of treatment (23).”
BackgroundMethodCushing's syndrome: epidemiology and developments in disease management
Feelders, R., Sharma, S., & Nieman, L. (2015) · Clinical Epidemiology · doi:10.2147/clep.s44336 · Cited by 210
“A small study of 17 patients showed an overall response rate of 88% after sequential addition of ketoconazole and/or cabergoline when initial pasireotide therapy was not successful.(146) Overall, medical treatment in Cushing’s syndrome needs to be individualized according to patient characteristics, potential side eff…”
Self-citationCabergoline monotherapy in the long-term treatment of Cushing's disease
Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O. D., & Lacroix, A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0382 · Cited by 202
Diabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment
van der Pas, R., Leebeek, F. W. G., Hofland, L. J., de Herder, W. W., & Feelders, R. A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12094 · Cited by 162
Self-citationGlucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome
Valassi, E., Crespo, I., Gich, I., Rodríguez, J., & Webb, S. M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04424.x · Cited by 91
Fleseriu, M., & Castinetti, F. (2016) · Pituitary · doi:10.1007/s11102-016-0742-1 · Cited by 87
Fleseriu, M., Hamrahian, A. H., Hoffman, A. R., Kelly, D. F., & Katznelson, L. (2016) · Endocrine Practice · doi:10.4158/ep161512.dscr · Cited by 68
Treatment of Cushing disease: overview and recent findings
Giustina, A. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s12952 · Cited by 66
“At day 60, 8 of 17 patients (47%) still had elevated UFC levels with the pasireotide–cabergoline combination, although a trend toward normalization was observed in all except one, with a mean decrease of 48% ± 6% in the level of UFC.(79)”
Nishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
Cardiovascular risk and mortality in patients with active and treated hypercortisolism
Li, D., El Kawkgi, O. M., Henriquez, A. F., & Bancos, I. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.03 · Cited by 42
Baroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., & Avogaro, A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0404-6 · Cited by 41
MacKenzie Feder, J., Bourdeau, I., Vallette, S., Beauregard, H., Ste-Marie, L.-G., & Lacroix, A. (2014) · Pituitary · doi:10.1007/s11102-013-0539-4 · Cited by 38
Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease
van der Pas, R., de Bruin, C., Pereira, A. M., Romijn, J. A., Netea-Maier, R. T., Hermus, A. R., Zelissen, P. M., de Jong, F. H., van der Lely, A. J., de Herder, W. W., et al. (2013) · Pituitary · doi:10.1007/s11102-012-0452-2 · Cited by 39
Self-citationMedical Therapy for Cushing’s Syndrome in the Twenty-first Century
Tritos, N. A., & Biller, B. M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.01.006 · Cited by 24
Metadata
- Authors
- Feelders, R. A., de Bruin, C., Pereira, A. M., Romijn, J. A., Netea-Maier, R. T., Hermus, A. R., Zelissen, P. M., van Heerebeek, R., de Jong, F. H., van der Lely, A.-J., de Herder, W. W., Hofland, L. J., & Lamberts, S. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-05-13
- Volume
- 362
- Issue
- 19
- Pages
- 1846-1848
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064762625
- Cited by
- 262
- References
- 5
- FWCI
- 16.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.